diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM10119diaendo-10119Research ArticleДискуссияDiscussionМодифицируется ли онкологическая заболеваемость под влиянием ингибиторов SGLT2?Is cancer incidence modified by SGLT2 inhibitors?https://orcid.org/0000-0002-5112-3372БерштейнЛев МихайловичBersteinLev M.

доктор медицинских наук, профессор, главный научный сотрудник лаборатории онкоэндокринологии

MD, PhD, Principap Scientific Researcher of the Laboratory of Oncoendocrinology

levmb@endocrin.spb.ruНациональный медицинский исследовательский центр онкологии им. Н.Н. ПетроваРоссияN.N.Petrov National Medical Research Center of OncologyRussian Federation201925102019224399402Copyright © Берштейн Л.М., 20192019Берштейн Л.М.Berstein L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/10119

Одним из ярких достижений диабетологии во втором десятилетии XXI в., несомненно, является внедрение в клиническую практику ингибиторов натрий-глюкозных котранспортеров (SGLT2) в качестве нового класса сахароснижающих препаратов при сахарном диабете 2 типа (СД2). Наряду с глюкозурией, индуцируемой этими средствами и рассматриваемой в качестве основного варианта достижения антидиабетического эффекта, прием ингибиторов SGLT2 сопровождается и некоторыми иными последствиями, часть из которых – в частности, в области онкологии – пока (в противоположность другим) исследованы недостаточно. В результате анализа доступных публикаций настоящее сообщение позволяет прийти к заключению о том, что онкологическая заболеваемость у больных СД2, лечившихся ингибиторами SGLT2, существенно не меняясь, может характеризоваться определенной органоспецифичностью, а с другой, стороны препараты этого класса могут оказаться полезными и при различных вариантах противоопухолевой терапии, что нуждается в дальнейшем изучении.

One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induced by these agents, which is their main pathway for achieving ‘antidiabetic recovery’, other consequences accompany the intake of SGLT2 inhibitors. These pathways, particularly in oncology, have not been extensively studied. Considering the analysis of the previous studies, this report demonstrates, although not significantly, that cancer morbidity in patients with T2DM treated with SGLT2 inhibitors may be organ-specific. In addition, agents within the class of SGLT-2 inhibitors may be useful in several variants of antitumor therapy, but this theory requires further study.

диабетингибиторы SGLT2глифлозинызлокачественные новообразованиязаболеваемостьлечениеdiabetesSGLT2 inhibitorsgliflozinsmalignant tumorsmorbiditytreatmentReferencesДедов И.И., Шестакова М.В., Викулова О.К., и др. Распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. // Сахарный диабет. — 2018. — Т. 21. — №3. — С. 144-159. [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: Prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal diabetes register, Status 2017. Diabetes mellitus. 2018;21(3):144-159. (In Russ.)] doi: https://doi.org/10.14341/DM9686Дедов И.И., Шестакова М.В., Викулова О.К., и др. Распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. // Сахарный диабет. — 2018. — Т. 21. — №3. — С. 144-159. [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: Prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal diabetes register, Status 2017. Diabetes mellitus. 2018;21(3):144-159. (In Russ.)] doi: https://doi.org/10.14341/DM9686Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности сахароснижающего действия и негликемические эффекты нового класса препаратов // Клиническая фармакология и терапия. — 2016. — Т. 25. — №2. — С. 65-71. [Shestakova MV, Sukhareva OY. Gliflozins: glucose-lowering and nonglycemic effects of new class of antidiabetic medications. Klinicheskaia farmakologiia i terapiia. 2016;25(2):65-71. (In Russ.)]Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности сахароснижающего действия и негликемические эффекты нового класса препаратов // Клиническая фармакология и терапия. — 2016. — Т. 25. — №2. — С. 65-71. [Shestakova MV, Sukhareva OY. Gliflozins: glucose-lowering and nonglycemic effects of new class of antidiabetic medications. Klinicheskaia farmakologiia i terapiia. 2016;25(2):65-71. (In Russ.)]Кобалава Ж.Д., Киякбаев Г.К. Сахарный диабет 2 типа и сердечно-сосудистые осложнения: можно ли улучшить прогноз назначением сахароснижающих препаратов // Российский кардиологический журнал. — 2018. — Т. 23. — №8. — С. 79-91. [Kobalava ZD, Kiyakbaev GК. Type 2 diabetes and cardiovascular complications: is it possible to improve prognosis by glucose lovering therapy? Russian Journal of Cardiology. 2018;23(8):79-91. (In Russ.)] doi: 10.15829/1560-4071-2018-8-79-91Кобалава Ж.Д., Киякбаев Г.К. Сахарный диабет 2 типа и сердечно-сосудистые осложнения: можно ли улучшить прогноз назначением сахароснижающих препаратов // Российский кардиологический журнал. — 2018. — Т. 23. — №8. — С. 79-91. [Kobalava ZD, Kiyakbaev GК. Type 2 diabetes and cardiovascular complications: is it possible to improve prognosis by glucose lovering therapy? Russian Journal of Cardiology. 2018;23(8):79-91. (In Russ.)] doi: 10.15829/1560-4071-2018-8-79-91Kuriyama S. Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials. Clin Exp Nephrol. 2018;23(3):304-312. doi: https://doi.org/10.1007/s10157-018-1673-0Kuriyama S. Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials. Clin Exp Nephrol. 2018;23(3):304-312. doi: https://doi.org/10.1007/s10157-018-1673-0Ishikawa N, Oguri T, Isobe T, et al. SGLT Gene Expression in Primary Lung Cancers and Their Metastatic Lesions. Jpn J Cancer Res. 2001;92(8):874-879. doi: https://doi.org/10.1111/j.1349-7006.2001.tb01175.xIshikawa N, Oguri T, Isobe T, et al. SGLT Gene Expression in Primary Lung Cancers and Their Metastatic Lesions. Jpn J Cancer Res. 2001;92(8):874-879. doi: https://doi.org/10.1111/j.1349-7006.2001.tb01175.xHome P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62(3):357-369. doi: https://doi.org/10.1007/s00125-018-4801-1Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62(3):357-369. doi: https://doi.org/10.1007/s00125-018-4801-1Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019;12:209-215. doi: https://doi.org/10.2147/DMSO.S184437Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019;12:209-215. doi: https://doi.org/10.2147/DMSO.S184437Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139(22):2528-2536. doi: https://doi.org/10.1161/circulationaha.119.040130Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139(22):2528-2536. doi: https://doi.org/10.1161/circulationaha.119.040130Maki T, Maeno S, Maeda Y, et al. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells. Sci Rep. 2019;9(1):4703. doi: https://doi.org/10.1038/s41598-019-41253-7Maki T, Maeno S, Maeda Y, et al. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells. Sci Rep. 2019;9(1):4703. doi: https://doi.org/10.1038/s41598-019-41253-7Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862-1872. doi: https://doi.org/10.1007/s00125-017-4370-8Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862-1872. doi: https://doi.org/10.1007/s00125-017-4370-8Shaikh AMY. SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia. 2017;60(12):2536-2537. doi: https://doi.org/10.1007/s00125-017-4434-9Shaikh AMY. SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia. 2017;60(12):2536-2537. doi: https://doi.org/10.1007/s00125-017-4434-9Kohler S, Lee J, George JT, et al. Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia. 2017;60(12):2534-2535. doi: https://doi.org/10.1007/s00125-017-4430-0Kohler S, Lee J, George JT, et al. Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia. 2017;60(12):2534-2535. doi: https://doi.org/10.1007/s00125-017-4430-0Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130(1):72-82. doi: https://doi.org/10.1080/00325481.2018.1394152Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130(1):72-82. doi: https://doi.org/10.1080/00325481.2018.1394152Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93. doi: https://doi.org/10.2174/1574886314666190206164647Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93. doi: https://doi.org/10.2174/1574886314666190206164647De Jonghe S, Proctor J, Vinken P, et al. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact. 2014;224:1-12. doi: https://doi.org/10.1016/j.cbi.2014.09.018De Jonghe S, Proctor J, Vinken P, et al. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact. 2014;224:1-12. doi: https://doi.org/10.1016/j.cbi.2014.09.018Shiba K, Tsuchiya K, Komiya C, et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 2018;8(1):2362. doi: https://doi.org/10.1038/s41598-018-19658-7Shiba K, Tsuchiya K, Komiya C, et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 2018;8(1):2362. doi: https://doi.org/10.1038/s41598-018-19658-7Billger M, Kirk J, Chang J, et al. A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin. Regul Toxicol Pharmacol. 2019;103:166-173. doi: https://doi.org/10.1016/j.yrtph.2019.01.031Billger M, Kirk J, Chang J, et al. A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin. Regul Toxicol Pharmacol. 2019;103:166-173. doi: https://doi.org/10.1016/j.yrtph.2019.01.031Saito T, Okada S, Yamada E, et al. Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J. 2015;62(12):1133-1137. doi: https://doi.org/10.1507/endocrj.EJ15-0396Saito T, Okada S, Yamada E, et al. Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J. 2015;62(12):1133-1137. doi: https://doi.org/10.1507/endocrj.EJ15-0396Kuang H, Liao L, Chen H, et al. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma. Med Sci Monit. 2017;23:3737-3745. doi: https://doi.org/10.12659/msm.902530Kuang H, Liao L, Chen H, et al. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma. Med Sci Monit. 2017;23:3737-3745. doi: https://doi.org/10.12659/msm.902530Kaji K, Nishimura N, Seki K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142(8):1712-1722. doi: https://doi.org/10.1002/ijc.31193Kaji K, Nishimura N, Seki K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142(8):1712-1722. doi: https://doi.org/10.1002/ijc.31193Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048-1056. doi: https://doi.org/10.1016/j.molmet.2016.08.014Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048-1056. doi: https://doi.org/10.1016/j.molmet.2016.08.014Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111-4119. doi: https://doi.org/10.1073/pnas.1511698112Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111-4119. doi: https://doi.org/10.1073/pnas.1511698112Kepe V, Scafoglio C, Liu J, et al. Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas. J Neurooncol. 2018;138(3):557-569. doi: https://doi.org/10.1007/s11060-018-2823-7Kepe V, Scafoglio C, Liu J, et al. Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas. J Neurooncol. 2018;138(3):557-569. doi: https://doi.org/10.1007/s11060-018-2823-7Scafoglio CR, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10(467). doi: https://doi.org/10.1126/scitranslmed.aat5933Scafoglio CR, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10(467). doi: https://doi.org/10.1126/scitranslmed.aat5933Kohler S, Zeller C, Iliev H, Kaspers S. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Adv Ther. 2017;34(7):1707-1726. doi: https://doi.org/10.1007/s12325-017-0573-0Kohler S, Zeller C, Iliev H, Kaspers S. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Adv Ther. 2017;34(7):1707-1726. doi: https://doi.org/10.1007/s12325-017-0573-0

The authors declare that there are no conflicts of interest present.